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Exosomes form part of the extracellular vesicle (EV) pool, consisting of different cell-derived structures generated from cytoplasmic and membrane components of their source cells. Exosomes are small membrane vesicles (30 -100 nm) and can be released from multi-vesicular bodies spontaneously or in response to external signals, such as mechanic and chemical stimuli. Exosomes, like other EV, can act as inter-cellular messengers delivering different RNA species (e.g. miRNA) and proteins to remote organs and cells.
1 Accordingly, exosomes can influence multiple biological processes such as immune responses 2, 3 or tumour growth 4 and consequently have gained much attention as therapeutic targets. However, one must not be blind sighted by their potential beneficial effects. In this issue of Cardiovascular Research, Aliotta and co-workers 5 extended their previous work on pulmonary hypertension (PAH) in mice by now pinpointing exosomes as the culprit EV fraction when inducing PAH by EV injection derived from monocrotaline (MCT)-treated mice. 6 Infusion of the exosome fraction from the total EV pool led to comparable pulmonary blood vessel wall thickening in relation to diameter as seen previously when injecting unfractionated EVs or MCT itself, whereas microvesicles, a larger species of EV, did not lead to PAH. In the current study, the authors aimed to shed light on the yet incompletely understood causal factors of pulmonary vessel remodelling in PAH by performing miRNA arrays on mouse-and human-derived exosomes. Of the 159 differentially regulated miRNAs in exosomes from MCT-treated mice, 11 showed similar up-or downregulation in exosomes from human PAH subjects. Reaching across different species renders these miRNAs interesting candidates for future mechanistic research on the pathogenesis of vascular remodelling in PAH. Particularly, mir-19b, mir-20a, mir-20b, and mir-145 were identified by Aliotta and co-workers as interesting candidates in this respect.
With the exception of mir-145, which has previously been shown to be involved in PAH in patients and mice alike, none of these miRNA has been linked to PAH before. 7 These results provide excellent starting points for future research to elucidate whether these findings are coincidental or provide a causal link. However, the authors did not further investigate the role of these miRNAs in PAH pathogenesis but set out to study the effects of exosomes from different sources instead to seek novel therapeutic avenues ( Figure 1 ).
To-date there is no cure for PAH, and current treatment modalities are symptomatic or directed at preventing complications. The most effective pharmaceutical treatments aim at reducing pulmonary artery pressure by dilating the pulmonary vasculature but cannot reverse the vessels' adverse remodelling. Remedy may be sought in the application of mesenchymal stem cells (MSC), which have been demonstrated to prevent hypoxia-induced PAH in mice. 8 The beneficial effects of MSC do not seem to be due to stem cell engraftment but rather a consequence of paracrine factors, likely via exosomes, released by these cells. 9 -12 Hence, application of the actual effectors might be faster, cheaper, and better controllable than cell therapy. In their current study, Aliotta and co-workers therefore preferred MSC-derived EV which they injected in the MCT PAH mouse model. In unison with earlier observations, the beneficial actions of MSC-derived EV were mediated by the exosome fraction and prevented right ventricular (RV) hypertrophy and pulmonary vessel wall thickening. Importantly, MSC-derived exosomes were not only able to prevent any signs of PAH, but also effectively reversed already existing PAH. When given 4 weeks after PAH induction, at a time point when PAH symptoms in mice are evident, MSC exosomes normalized RV weight and vessel wall thickness. Interestingly, these effects were not species specific as both exosomes from mouse as well as human MSCs showed the same therapeutic efficacy on RV remodelling reversal. At the same time, mice injected with the vehicle did not show any significant improvement, albeit that they did not show any worsening either. As with all chronic disease mouse models, it remains to be shown whether the presence of a disease for 4 or 8 weeks in a mouse adequately reflects a human disease that develops within years to decades to allow translating these findings into the clinic. This may be a long shot at this moment and we are only starting to understand the multitude of exosomes with possible wanted or unwanted effects. Most likely, MSC-derived exosomes will not show comparable efficacy in human PAH, but this study provides further candidates to find the 'sweet spot' for causal PAH treatment nonetheless by showing offending and beneficial effects of exosomes alike depending on their cellular source and content. The authors took every caution to ensure that the MSC exosome preparation was free of contaminating exosomes that might be present in the culture media used for their studies. 6 The opinions expressed in this article are not necessarily those of the Editors of Cardiovascular Research or of the European Society of Cardiology.
Considering the abundance of stimuli resulting in exosome release, it is crucial to note that the MSC exosomes in this study might markedly differ from MSC exosomes in other studies due to different material or culturing conditions. In the worst case, adding, changing, or omitting any element to the exosome manufacturing process might turn a therapeutic exosome harmful as elegantly shown by the divergent effects of MCT and MSC exosomes in the current study. First steps towards large-scale production of MSC exosomes have been made showing its technical feasibility. 13 All the more, the versatility of exosomes underscores the need for proper characterization and standardization in exosome research, be it for diagnostic, prognostic, or therapeutic uses. 
